FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092245836> ?p ?o ?g. }

• W3092245836 endingPage "709" @default.
• W3092245836 startingPage "705" @default.
• W3092245836 abstract "Abstract Background & Aims There is emerging data on the use of Sofosbuvir‐based directly acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with end‐stage renal disease (ESRD) on maintenance haemodialysis (MHD). We evaluated the safety and efficacy of Sofosbuvir plus Velpatasvir fixed‐dose combination in CHC patients with ESRD on MHD. Methods Fifty‐one CHC patients with ESRD on MHD were included in a real‐life prospective study. All patients irrespective of genotype; presence of cirrhosis; treatment naive or experienced status were treated with full‐dose Sofosbuvir (400 mg) plus Velpatasvir (100 mg) fixed‐dosed combination given daily for 12 weeks. The efficacy was assessed by the sustained virological response (SVR12) with negative HCV RNA 12 weeks after the end of treatment (ETR). Side effects if any were recorded in all patients. Results The median HCV RNA level in 51 CHC patients [Males 41 (80.4%), mean age 42.8 ± 14.6 years] was 2.0 × 10 6 IU/mL. HCV genotype was available in 19 patients with predominant genotype 1 in 15 (79%) patients. Ten (19.6%) patients had evidence of cirrhosis (defined as LSM ≥ 12.5 kPa on Transient Elastography), and 8 (15.6%) patients were treatment experienced. Testing for ETR was done in 36 patients and all 36 (100%) patients achieved ETR, and 49 patients (96%) achieved SVR 12. All 51 patients tolerated the Sofosbuvir + Velpatasvir combination, with none of the patients reporting any serious adverse event. Conclusion Sofosbuvir plus Velpatasvir fixed‐dose combination is safe and effective in treating CHC in patients with ESRD on MHD." @default.
• W3092245836 created "2020-10-15" @default.
• W3092245836 creator A5000607778 @default.
• W3092245836 creator A5027620539 @default.
• W3092245836 creator A5030307548 @default.
• W3092245836 creator A5037076474 @default.
• W3092245836 creator A5040682018 @default.
• W3092245836 creator A5044538545 @default.
• W3092245836 creator A5045640684 @default.
• W3092245836 creator A5048552465 @default.
• W3092245836 creator A5068365064 @default.
• W3092245836 creator A5078341368 @default.
• W3092245836 creator A5083857141 @default.
• W3092245836 creator A5086116099 @default.
• W3092245836 creator A5090656568 @default.
• W3092245836 date "2021-03-17" @default.
• W3092245836 modified "2023-10-03" @default.
• W3092245836 title "Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis" @default.
• W3092245836 cites W1874082200 @default.
• W3092245836 cites W2015283030 @default.
• W3092245836 cites W2099249529 @default.
• W3092245836 cites W2177600636 @default.
• W3092245836 cites W2185218296 @default.
• W3092245836 cites W2337799375 @default.
• W3092245836 cites W2464297389 @default.
• W3092245836 cites W2512016797 @default.
• W3092245836 cites W2606291812 @default.
• W3092245836 cites W2734474168 @default.
• W3092245836 cites W2750541065 @default.
• W3092245836 cites W2754580087 @default.
• W3092245836 cites W2760528995 @default.
• W3092245836 cites W2761085897 @default.
• W3092245836 cites W2767121148 @default.
• W3092245836 cites W2783893732 @default.
• W3092245836 cites W2793357379 @default.
• W3092245836 cites W2803034834 @default.
• W3092245836 cites W2885103621 @default.
• W3092245836 cites W2887630074 @default.
• W3092245836 cites W2890778396 @default.
• W3092245836 cites W2901843950 @default.
• W3092245836 cites W2904058346 @default.
• W3092245836 cites W2906212848 @default.
• W3092245836 cites W2908140382 @default.
• W3092245836 cites W2911833730 @default.
• W3092245836 cites W2914591971 @default.
• W3092245836 cites W2915172056 @default.
• W3092245836 cites W2925171401 @default.
• W3092245836 cites W2939225366 @default.
• W3092245836 cites W2950823694 @default.
• W3092245836 cites W2985173551 @default.
• W3092245836 cites W4323521971 @default.
• W3092245836 doi "https://doi.org/10.1111/liv.14685" @default.
• W3092245836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33025685" @default.
• W3092245836 hasPublicationYear "2021" @default.
• W3092245836 type Work @default.
• W3092245836 sameAs 3092245836 @default.
• W3092245836 citedByCount "19" @default.
• W3092245836 countsByYear W30922458362021 @default.
• W3092245836 countsByYear W30922458362022 @default.
• W3092245836 countsByYear W30922458362023 @default.
• W3092245836 crossrefType "journal-article" @default.
• W3092245836 hasAuthorship W3092245836A5000607778 @default.
• W3092245836 hasAuthorship W3092245836A5027620539 @default.
• W3092245836 hasAuthorship W3092245836A5030307548 @default.
• W3092245836 hasAuthorship W3092245836A5037076474 @default.
• W3092245836 hasAuthorship W3092245836A5040682018 @default.
• W3092245836 hasAuthorship W3092245836A5044538545 @default.
• W3092245836 hasAuthorship W3092245836A5045640684 @default.
• W3092245836 hasAuthorship W3092245836A5048552465 @default.
• W3092245836 hasAuthorship W3092245836A5068365064 @default.
• W3092245836 hasAuthorship W3092245836A5078341368 @default.
• W3092245836 hasAuthorship W3092245836A5083857141 @default.
• W3092245836 hasAuthorship W3092245836A5086116099 @default.
• W3092245836 hasAuthorship W3092245836A5090656568 @default.
• W3092245836 hasConcept C126322002 @default.
• W3092245836 hasConcept C141071460 @default.
• W3092245836 hasConcept C197934379 @default.
• W3092245836 hasConcept C203014093 @default.
• W3092245836 hasConcept C2522874641 @default.
• W3092245836 hasConcept C2776408679 @default.
• W3092245836 hasConcept C2776455275 @default.
• W3092245836 hasConcept C2777214474 @default.
• W3092245836 hasConcept C2778063415 @default.
• W3092245836 hasConcept C2778390639 @default.
• W3092245836 hasConcept C2780040827 @default.
• W3092245836 hasConcept C3019040382 @default.
• W3092245836 hasConcept C71924100 @default.
• W3092245836 hasConcept C90924648 @default.
• W3092245836 hasConceptScore W3092245836C126322002 @default.
• W3092245836 hasConceptScore W3092245836C141071460 @default.
• W3092245836 hasConceptScore W3092245836C197934379 @default.
• W3092245836 hasConceptScore W3092245836C203014093 @default.
• W3092245836 hasConceptScore W3092245836C2522874641 @default.
• W3092245836 hasConceptScore W3092245836C2776408679 @default.
• W3092245836 hasConceptScore W3092245836C2776455275 @default.
• W3092245836 hasConceptScore W3092245836C2777214474 @default.
• W3092245836 hasConceptScore W3092245836C2778063415 @default.
• W3092245836 hasConceptScore W3092245836C2778390639 @default.

• next